Plasmin-resistant streptokinase
AssigneePresident and Fellows of Harvard College
InventorGuy L. Reed
Life of this patent
Estimating the term…
Abstract
The invention features modified streptokinase (SK) molecules which are resistant to plasmin cleavage including a recombinant fusion protein in which the amino terminus of SK was blocked with a peptide, a recombinant fusion protein in which an amino-terminal deleted SK was blocked with a peptide, and a mutated SK in which plasmin-cleavage sites were altered to render those sites resistant to enzymatic cleavage.
Claims8
A plasminogen-binding fragment of streptokinase, wherein
- (a) said fragment lacks 1 to 24 amino-terminal amino acids;
- (b) said fragment is catalytically active;
- and
- (c) the rate of in vitro degradation of said fragment in the presence of human plasminogen is at least 2 times slower compared to the rate of degradation of native streptokinase in the presence of human plasminogen, wherein the rate of degradation is measured by the appearance of plasmin cleavage products as detected by immunoblotting using anti-streptokinase antibodies, and
- (d) wherein said fragment further comprises at least one mutation in a potential plasmin cleavage site which renders said cleavage site resistant to cleavage by plasmin.
A polypeptide comprising a plasminogen-binding fragment of streptokinase, wherein
- (a) said fragment is catalytically active;
- and
- (b) the rate of in vitro degradation of said polypeptide in the presence of human plasminogen is at least two times slower compared to the rate of degradation of native streptokinase in the presence of human plasminogen, wherein the rate of degradation is measured by the appearance of plasmin cleavage products as detected by immunoblotting using anti-streptokinase antibodies, and
- (c) wherein said polypeptide further comprises at least one mutation in a potential plasmin cleavage site which renders said cleavage site resistant to cleavage by plasmin.
A compound comprising (a) a plasminogen-binding fragment of streptokinase and (b) a blocking group at the amino-terminus of said fragment, wherein
- (i) said compound is catalytically active;
- and
- (ii) the rate of in vitro degradation of said compound in the presence of human plasminogen is at least 2 times slower compared to the rate of degradation of native streptokinase in the presence of human plasminogen, wherein the rate of degradation is measured by the appearance of plasmin cleavage products as detected by immunoblotting using anti-streptokinase antibodies, and
- (iii) said blocking group is a non-peptide blocking group.
Dependencies are inferred from the claim text.